Abstract | INTRODUCTION: AREAS COVERED: Role of XIAP in apoptosis pathways, structure of AEG 35156, mechanism of action, pharmacokinetics and pharmacodynamics, clinical efficacy and review of clinical trials in AML. EXPERT OPINION:
AEG 35156 in combination with standard chemotherapy was generally very well-tolerated and had shown some evidence of anti-leukemic activity in AML. The target knock down was transient and has not always correlated with response. Future studies may be done with variations in dose scheduling and with more emphasis on comprehensive pharmacodynamic studies simultaneously analyzing other inhibitor of apoptosis proteins (IAPs) and various XIAP regulators. Use of small molecule mimetics of second mitochondria derived activator of caspases (Smac) simultaneously targeting other IAPs appears to be an attractive option.
|
Authors | Lakshmikanth Katragadda, Bing Z Carter, Gautam Borthakur |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 22
Issue 5
Pg. 663-70
(May 2013)
ISSN: 1744-7658 [Electronic] England |
PMID | 23586880
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- AEG 35156
- Antineoplastic Agents
- Oligonucleotides
- Oligonucleotides, Antisense
- X-Linked Inhibitor of Apoptosis Protein
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Humans
- Leukemia, Myeloid, Acute
(drug therapy, metabolism)
- Oligonucleotides
(pharmacology, therapeutic use)
- Oligonucleotides, Antisense
(pharmacology, therapeutic use)
- X-Linked Inhibitor of Apoptosis Protein
(metabolism)
|